PAOG Path To $0.01 Breakout On $14B Cannabis Biopharma News Is Paved in Recent Consolidation
July 29 2020 - 11:08AM
InvestorsHub NewsWire
July 29, 2020 --
InvestorsHub NewsWire -- via NextBigTicker
--
PAO Group, Inc.
(USOTC:
PAOG) has had consistently high trading volume after announcing
a management takeover and two pending acquisitions. The PPS
climbed rapidly from $0.0003 all the way to a new 52-Week High of
$0.0059 and has since been consolidating well above both the 50 Day
and 200 Day Moving Averages at a PPS between $0.0026 and
$0.0035.
Short sellers
are actively covering. PAOG is listed as one of the most
shorted stocks on the OTC Short Report
(https://www.otcshortreport.com/company/PAOG)
based on data from FINRA’s Short Volume Report. With the big
recent volume taking the PPS to $0.0059 all above all above
$0.0025, shorts are likely happy to be covering anywhere under
$0.003. The $0.003 PPS is likely a short squeeze trigger and
solid trading volume above $0.003 is likely to see short converging
contribution to PPS gains.
$14 Billion
Cannabis Biopharmaceutical
News
PAOG has its
second acquisition for the week scheduled to close tomorrow, July
28. This is the big one. The company is acquiring a
patented cannabis extraction operation from Kali-Extracts
(KALY). The operation comes with a drug called RespRx under
development. RespRx is a treatment for
Chronic Obstructive Pulmonary Disease
(COPD). Across the eight
major economic markets of the US, France, Germany, Italy, Spain,
the UK, Japan, and Australia, the COPD treatment market is
anticipated to rise from $9.9 billion in 2015 to around $14.1
billion by 2025.
The $14 Billion
news has the potential to triger the PAOG PPS climb over a $0.01
PPS from its current $0.002 to $0.003 PPS range and go as high as
$0.10.
The patented
cannabis extraction process acquisition might also be harboring a
secret weapon against
COVID-19.
In January,
KALY announced the potential treatment of
COVID-19 symptoms:
“Kali-Extracts, Inc. today highlighted that its
RespRx CBD formulation could offer treatment for coronavirus
symptoms. KALY's CBD formulation has been developed for the
treatment of symptoms associated with Chronic
Obstructive Pulmonary Disease (COPD) and other
similar respiratory conditions. The
formulation for the treatment of symptoms associated with COPD and
other similar respiratory conditions has been derived from the
company's U.S. Patented Cannabis Extraction Process. In conjunction
with the research already conducted and the next phase of research
now moving forward, KALY has filed a new patent application
specifically on its CPD formulation for symptoms associated with
COPD and other similar respiratory
conditions. KALY has also filed for a
trademark on the name RespRx as the
brand name for its CBD formulation to treat the symptoms associated
with COPD and other similar respiratory
conditions.”
Multiple
articles have recently been published from highly reputable sources
on the potential for cannabis to treat COVID-19 symptoms. Here are
just a few:
The PAOG PPS was
over $0.01 in January of 2019 and little is standing in the way of
the PPS rapidly returning to the $0.01
level.
Disclaimer:
NextBigTicker.com (NBT)is a third party publisher
and news dissemination service provider. NBT is NOT affiliated
in any manner with any company mentioned herein. NBT is news
dissemination solutions provider and are NOT a registered
broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. NBT's
market updates, news alerts and corporate profiles are NOT a
solicitation or recommendation to buy, sell or hold securities. The
material in this release is intended to be strictly informational
and is NEVER to be construed or interpreted as research material.
All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial
professional before considering any level of investing in
stocks. All material included herein is republished content
and details which were previously disseminated by the companies
mentioned in this release or opinion of the writer. NBT is not
liable for any investment decisions by its readers or subscribers.
Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. NBT has not been
compensated for this release and HOLDS NO SHARES OF ANY
COMPANY NAMED IN THIS
RELEASE.
Disclaimer/Safe
Harbor:
This news release contains forward-looking statements within the
meaning of the Securities Litigation Reform Act. The statements
reflect the Company's current views with respect to future events
that involve risks and uncertainties. Among others, these risks
include the expectation that any of the companies mentioned herein
will achieve significant sales, the failure to meet schedule or
performance requirements of the companies' contracts, the
companies' liquidity position, the companies' ability to obtain new
contracts, the emergence of competitors with greater financial
resources and the impact of competitive pricing. In the light of
these uncertainties, the forward-looking events referred to in this
release might not occur.
Source: www.nextbigticker.com
Other companies on the OTC Short Report most shorted list include:
BBRW,
BYOC and
PVDG.
SOURCE: NextBigTicker